Dermata Therapeutics
DRMA
4 hedge funds and large institutions have $47.4K invested in Dermata Therapeutics in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, reducing their positions, and 7 closing their positions.
0.03% more ownership
Funds ownership: 0% → 0.03% (+0.03%)
60% less funds holding
Funds holding: 10 → 4 (-6)
60% less capital invested
Capital invested by funds: $119K → $47.4K (-$71.4K)
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$103K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$21.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$4.08K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$58K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$10K |
| 3 |
FWP
FAS Wealth Partners
Leawood,
Kansas
|
-$5.19K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$5.09K |
| 5 |
SCA
Sage Capital Advisors
Sioux Falls,
South Dakota
|
-$4.91K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $34K | +$103K | +176 | New |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $7K | +$21.6K | +37 | +1,850% |
|
|
3
UBS Group
Zurich,
Switzerland
| $4.44K | +$4.08K | +7 | +44% |
|
4
Wells Fargo
San Francisco,
California
| $1.97K | – | – | – |
|
|
RJFSA
5
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| – | -$58K | -59 | Closed |
|
|
6
Geode Capital Management
Boston,
Massachusetts
| – | -$10K | -11 | Closed |
|
|
FWP
7
FAS Wealth Partners
Leawood,
Kansas
| – | -$5.19K | -5 | Closed |
|
|
SCA
8
Sage Capital Advisors
Sioux Falls,
South Dakota
| – | -$4.91K | -5 | Closed |
|
|
TSS
9
Two Sigma Securities
New York
| – | -$5.09K | -5 | Closed |
|
|
HA
10
HC Advisors
Sandy Springs,
Georgia
| – | -$4.09K | -4 | Closed |
|
11
Tudor Investment Corp
Stamford,
Connecticut
| – | -$4K | -4 | Closed |
|
12
Morgan Stanley
New York
| – | -$230 | – | – |
|
DRMA Hedge Fund Activity: Q1 2023 in Review
4 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics (DRMA) for Q1 2023, worth a combined $47.4K — down 60% from $119K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of DRMA and 1 opened new positions — a net loss of 6 holders — while 0 trimmed existing stakes and 2 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $103K. The largest seller was Raymond James Financial Services Advisors, exiting entirely with an estimated $58K sold.
- 4 institutional investors held Dermata Therapeutics (DRMA) as of Q1 2023, down from 10 in Q4 2022.
- Funds reported $47.4K of Dermata Therapeutics stock for Q1 2023, down 60% quarter-over-quarter.
- 1 fund opened new Dermata Therapeutics positions in Q1 2023 and 7 closed out, a net change of -6 holders.
- The largest Dermata Therapeutics buyer in Q1 2023 was Renaissance Technologies, an estimated $103K added.
- The largest Dermata Therapeutics seller in Q1 2023 was Raymond James Financial Services Advisors, an estimated $58K sold.
Based on aggregated 13F filings for Q1 2023.